Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Cat's claw (Uncaria tomentosa) is a native amazonic plant that exhibits anti-inflammatory and
antitumor properties. Patients and methods: This prospective phase II study will assess the
effects of a 100-mg dose of a dry extract of U. tomentosa three times per day on individuals
with advanced solid tumors, with no further therapeutic options and with at least 2 months
life expectancy. In addition, several biochemical and inflammatory parameters will be
analyzed.